MCID: MTR088
MIFTS: 42

Mature T-Cell and Nk-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Mature T-Cell and Nk-Cell Lymphoma

MalaCards integrated aliases for Mature T-Cell and Nk-Cell Lymphoma:

Name: Mature T-Cell and Nk-Cell Lymphoma 12 15
Mature T-Cell and Natural Killer Cell Lymphoma 12
Nk-T Cell Lymphoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050743
ICD10 32 C86

Summaries for Mature T-Cell and Nk-Cell Lymphoma

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in mature T lymphocytes and natural killer cells.

MalaCards based summary : Mature T-Cell and Nk-Cell Lymphoma, also known as mature t-cell and natural killer cell lymphoma, is related to peripheral t-cell lymphoma and cellulitis. An important gene associated with Mature T-Cell and Nk-Cell Lymphoma is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Cell adhesion molecules and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Mechlorethamine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and liver.

Related Diseases for Mature T-Cell and Nk-Cell Lymphoma

Diseases related to Mature T-Cell and Nk-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)
# Related Disease Score Top Affiliating Genes
1 peripheral t-cell lymphoma 32.7 TNFRSF8 TIA1 NCAM1 CD8A CD5 ALK
2 cellulitis 31.6 CD8A CD4 CCR6
3 b-cell lymphoma 31.6 TNFRSF8 TIA1 MIR17 CD5 ALK
4 t-cell lymphoma, subcutaneous panniculitis-like 31.5 TNFRSF8 TIA1 CD7 ALK
5 diffuse large b-cell lymphoma 31.5 TNFRSF8 MIR199A1 MIR17 CD5 ALK
6 allergic disease 31.3 TNFRSF8 ICOSLG CD5 CCR6
7 lethal midline granuloma 31.2 TNFRSF8 TIA1 NCAM1 CD7 CD2
8 nasal cavity lymphoma 31.2 TIA1 NCAM1 CD5 CD2
9 aggressive nk-cell leukemia 31.2 TIA1 NCAM1 CD7 CD5 CD2
10 anaplastic large cell lymphoma 31.2 TNFRSF8 TIA1 CD4 ALK
11 panniculitis 31.2 TNFRSF8 TIA1 NCAM1 CD8A CD4
12 pancytopenia 31.2 NCAM1 H2AC18 CD8A CD7 CD5 CD4
13 lung lymphoma 31.2 TNFRSF8 CD5
14 orbital cellulitis 31.1 TNFRSF8 NCAM1 CD4
15 lymphoproliferative syndrome 31.1 TNFRSF8 TIA1 CD5 CCR6 ALK
16 lymphoma 31.1 TNFRSF8 TIA1 MIA2 CD5 CCR6 ALK
17 lymphadenitis 31.1 ICOSLG CD8A CD4 CCR6
18 cutaneous t cell lymphoma 31.0 TNFRSF8 TIA1 MIA2 CCR6
19 syphilis 31.0 CD8A CD4 CCR6
20 composite lymphoma 31.0 TNFRSF8 TIA1 CD5
21 pericardial effusion 31.0 TNFRSF8 CD4 ALK
22 histiocytosis 31.0 TNFRSF8 CCR6 ALK
23 lymphoma, hodgkin, classic 30.9 TNFRSF8 TIA1 KDM4C ICOSLG ALK
24 t-cell lymphoblastic leukemia/lymphoma 30.9 TNFRSF8 CD7 CD4 CCR6
25 mycosis fungoides 30.9 TNFRSF8 TIA1 NCAM1 MIR200C CD7 CCR6
26 respiratory failure 30.8 H2AC18 CD8A CD4 CCR6
27 castleman disease 30.8 TNFRSF8 H2AC18 CD4
28 alk-positive anaplastic large cell lymphoma 30.8 TNFRSF8 ALK
29 orbit lymphoma 30.8 TIA1 NCAM1
30 dacryoadenitis 30.7 ICOSLG CD8A CD4 CCR6
31 panuveitis 30.7 ICOSLG CD8A CD4 CCR6
32 adult t-cell leukemia 30.7 TNFRSF8 CD7 CD4 CCR6
33 tertiary syphilis 30.7 CD8A CD4
34 leprosy 3 30.7 CD8A CD4 CCR6
35 laryngeal disease 30.7 MIR17 H2AC18 CCR6
36 pfeiffer syndrome 30.7 TNFRSF8 H2AC18 CD8A CD4 CCR6
37 exanthem 30.7 ICOSLG H2AC18 CD8A CD4 CCR6
38 combined immunodeficiency 30.6 ICOSLG CD8A CD7 CD4 CCR6
39 bone inflammation disease 30.5 MIR199A1 MIR17 ICOSLG H2AC18 CD8A CD4
40 skin carcinoma 30.4 NCAM1 MIR17 ICOSLG H2AC18 CD8A CD4
41 immune deficiency disease 30.3 MIR199A1 MIR17 ICOSLG H2AC18 CD8A CD5
42 peripheral nervous system disease 30.2 NCAM1 MIR199A1 MIR17 KDM4C ICOSLG H2AC18
43 lymphoma, non-hodgkin, familial 30.2 TNFRSF8 NCAM1 MIR199A1 MIR17 MIA2 KDM4C
44 leukemia, chronic lymphocytic 30.2 TNFRSF8 NCAM1 MIR199A1 MIR17 KDM4C ICOSLG
45 leukemia, acute lymphoblastic 30.2 MIR199A1 MIR17 KDM4C ICOSLG H2AC18 CD8A
46 nasal type extranodal nk/t-cell lymphoma 11.5
47 neutropenia 10.7
48 pityriasis lichenoides 10.6 TNFRSF8 CD7
49 pityriasis lichenoides et varioliformis acuta 10.6 TNFRSF8 CD7
50 american histoplasmosis 10.6 TNFRSF8 CD4

Graphical network of the top 20 diseases related to Mature T-Cell and Nk-Cell Lymphoma:



Diseases related to Mature T-Cell and Nk-Cell Lymphoma

Symptoms & Phenotypes for Mature T-Cell and Nk-Cell Lymphoma

Drugs & Therapeutics for Mature T-Cell and Nk-Cell Lymphoma

Drugs for Mature T-Cell and Nk-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
2
Etoposide Approved Phase 4 33419-42-0 36462
3 BB 1101 Phase 4
4 Protective Agents Phase 4
5 HIV Protease Inhibitors Phase 4
6
protease inhibitors Phase 4
7 Histone Deacetylase Inhibitors Phase 4
8 Angiogenesis Inhibitors Phase 4
9 Etoposide phosphate Phase 4
10 Antibodies, Blocking Phase 4
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
12
leucovorin Approved Phase 3 58-05-9 6006
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14 Folic Acid Antagonists Phase 3
15 Vitamin B Complex Phase 3
16 Vitamin B9 Phase 3
17 Dermatologic Agents Phase 3
18 Calcium, Dietary Phase 3
19 Anti-Bacterial Agents Phase 3
20 Folate Phase 3
21
Calcium Nutraceutical Phase 3 7440-70-2 271
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
24
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
27
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
28
Melphalan Approved Phase 2 148-82-3 4053 460612
29
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
32
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
33
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
34
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
35
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
38
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
39
Pembrolizumab Approved Phase 2 1374853-91-4
40
Pegaspargase Approved, Investigational Phase 1, Phase 2 130167-69-0
41
Lenalidomide Approved Phase 2 191732-72-6 216326
42
Basiliximab Approved, Investigational Phase 2 179045-86-4, 152923-56-3
43
Tofacitinib Approved, Investigational Phase 2 477600-75-2
44
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
45
Durvalumab Approved, Investigational Phase 2 1428935-60-7
46
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
47
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Ipilimumab Approved Phase 1, Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
2 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
3 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Recruiting NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
4 A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Recruiting NCT04490590 Phase 4 Chidamide+ Etoposide
5 A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) Recruiting NCT04365036 Phase 3 Toripalimab;Pegaspargase;Gemcitabine;Oxaliplatin
6 The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
7 PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients:a Randomized, Open-label, Phase 3 Study Active, not recruiting NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
8 An Open-Label, Uncontrolled, Single Centered Phase Ⅱ Study of Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone (Avastin+ GemAOD) As First-Line Treatment in Patients With Untreated NK/T Cell Lymphoma Unknown status NCT01921790 Phase 2 Gemcitabine;Oxaliplatin;Pegaspargase;Dexamethasone
9 An Open, Single-center, Phase II Clinical Trial for Treatment of Untreated Extranodal NK/T Cell Lymphoma With High Dose of Methotrexate in Combination With Gemcitabine, Pegaspargase and Dexamethasone (GAD-M Regimen) Unknown status NCT01991158 Phase 2 High dose of methotrexate;Gemcitabine;Pegaspargase;Dexamethasone
10 A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Latent Membrane Protein-2a [LMP2A] Specific Eutil Autologous Blood-derived T Lymphocytes) in Patients With Progressive Epstein-Barr Virus (EBV) Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed Unknown status NCT03789617 Phase 1, Phase 2
11 A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma Unknown status NCT01667302 Phase 2 Radiotherapy followed by chemotherapy
12 Single-arm, Open and Multi-center Phase II Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Unknown status NCT03776279 Phase 2 Mitoxantrone Hydrochloride Liposome Injection
13 Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma Unknown status NCT00568607 Phase 2 IFO, VP-16, DDP, DXM
14 Mild-dose Intensity-modulated Radiation Treatment for Stage IE/IIE Extranodal Nasal-type NK/T-cell Lymphoma With Complete Remission Tumor After Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) Chemotherapy:a Phase II Study Unknown status NCT02229682 Phase 2
15 Phase II Study of L-asparaginase Plus DICE Regimen in Patients With Stage I/II NK/T-cell Lymphoma Unknown status NCT00933673 Phase 2 L-asp, DXM, IFO, VP-16, DDP
16 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
17 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
18 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
19 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
20 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
21 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
22 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01238159 Phase 2
23 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
24 Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Patients With Unfavorable Prognostic Factors: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT02276248 Phase 2 GDP chemotherapy
25 Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01007526 Phase 2
26 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
27 A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-cell Lymphoma Completed NCT00292695 Phase 2
28 A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma Completed NCT00418535 Phase 2 Concurrent Radiotherapy (RT)/cisplatin, VIPD
29 Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma Completed NCT00283985 Phase 2 Kidrolase;Methotrexate;Dexamethasone;Erwinase
30 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
31 Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4) Completed NCT03228836 Phase 2 Sintilimab
32 Phase II Study of L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma Completed NCT00854425 Phase 2 L-asparaginase
33 A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade
34 PD-1 Blockade With Pembrolizumab in Relapsed/Refractory Mature T-cell and NK-cell Lymphomas Recruiting NCT03021057 Phase 2 pembrolizumab
35 Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma Recruiting NCT02544425 Phase 2 Etoposide;Ifosfamide;Dexamethasone;L-asparaginase;Busulfan;Melphalan
36 Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type), a Multicenter, Open-label Phase Ib/II Trial Recruiting NCT04602065 Phase 1, Phase 2 IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
37 Combination of Lenalidomide and Sintilimab for Patients With Relapsed/Refractory NK/T-cell Lymphoma Who Failed Pegaspargase-based Regimens: a Single Arm, Open, Phase II Study Recruiting NCT04231370 Phase 2 Sintilimab;Lenalidomide
38 Sintilimab With P-GemOx (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (ENKTL): a Single Arm, Open, Multicenter, Phase II Study Recruiting NCT04127227 Phase 2 sintilimab,pegaspargase,gemcitabine,oxaliplatin
39 Combination of Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study Recruiting NCT04279379 Phase 2 Sintilimab;Decitabine
40 Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma Recruiting NCT03246750 Phase 1, Phase 2 B-MAD chemotherapy
41 A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients Recruiting NCT03671850 Phase 2
42 Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
43 Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type Recruiting NCT03728972 Phase 2 Pembrolizumab
44 The Efficacy and Safety of Anti-PD-1 Antibody in Combination With Pegaspargase in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT04096690 Phase 2 Pegaspargase;Anti-PD-1 monoclonal antibody
45 A Prospective Phase II Study of Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Patients With Newly Diagnosed Extra-nodal NK/T-cell Lymphoma Recruiting NCT04484506 Phase 2 pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone
46 An Open-label, Single-arm, Global Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Recruiting NCT04414163 Phase 2 IMC-001
47 Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study Recruiting NCT04405375 Phase 2 gemcitabin;Pegaspargase;Etoposide;Dexamethasone
48 Phase 2 Trial of PEG-ASP Combined With Etoposide and Gemcitabine (PEG) as First-line Chemotherapy to Treat NK/T-cell Lymphoma Recruiting NCT02705508 Phase 2 Gemcitabine;etoposide;Pegaspargase
49 A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody (Sintilimab) in Combination With Pegaspargase and Erlotinib in the Treatment of Stage IV Extranodal NK/T-cell Lymphoma Unfit for High-intensity Chemotherapy Recruiting NCT04004572 Phase 2 LEAP regimen
50 An Open, Multi-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma Recruiting NCT03936452 Phase 2 Sintilimab

Search NIH Clinical Center for Mature T-Cell and Nk-Cell Lymphoma

Genetic Tests for Mature T-Cell and Nk-Cell Lymphoma

Anatomical Context for Mature T-Cell and Nk-Cell Lymphoma

MalaCards organs/tissues related to Mature T-Cell and Nk-Cell Lymphoma:

40
Skin, T Cells, Liver, Bone Marrow, Brain, Breast, Testis

Publications for Mature T-Cell and Nk-Cell Lymphoma

Articles related to Mature T-Cell and Nk-Cell Lymphoma:

(show top 50) (show all 1502)
# Title Authors PMID Year
1
A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand. 61
33427594 2021
2
[Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma]. 61
33554802 2021
3
Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma. 61
33140135 2021
4
Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient. 61
33580279 2021
5
Modern Radiotherapy for Extranodal Nasal-type NK/T-cell Lymphoma: Risk-adapted Therapy, Target Volume and Dose Guidelines from the International Lymphoma Radiation Oncology Group. 61
33581262 2021
6
Extranodal NK/T cell lymphoma, nasal type, mimicking a bullous pyoderma gangrenosum. 61
33527364 2021
7
Signaling pathways of EBV-induced oncogenesis. 61
33549103 2021
8
An Unusual Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Masquerading as Dacryocystitis and Sinusitis. 61
33559497 2021
9
Allogeneic Haematopoietic Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma. 61
33535731 2021
10
Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population. 61
33242451 2021
11
Lymphoma subtypes in India: a tertiary care center review. 61
33481141 2021
12
Extranodal NK/T cell lymphoma, nasal type: An updated overview. 61
33493634 2021
13
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. 61
32152465 2021
14
LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma. 61
33391513 2021
15
Analysis of clinical effect of PD-1 inhibitor combined with chemotherapy in the treatment of nasal type NK/T cell lymphoma. 61
33494564 2021
16
Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents. 61
33484107 2021
17
Nasal-type extranodal NK/T-cell lymphoma: a diagnostic challenge. 61
33514618 2021
18
Discordant lymphoma consisting of NK/T-cell lymphoma and Hodgkin's lymphoma seen on FDG PET. 61
33509690 2021
19
Chronic active EBV infection in refractory enteritis with longitudinal ulcers with a cobblestone appearance: an autopsied case report. 61
33407170 2021
20
Primary extranodal natural Killer/T-cell lymphoma in a child in the colon: A case report. 61
33546043 2021
21
The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. 61
33468080 2021
22
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. 61
33205337 2021
23
PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge? 61
33009482 2020
24
[Intraocular involvement of extranodal NK/T-cell lymphoma, nasal type: two cases report]. 61
33445857 2020
25
Staging challenges in extranasal and juvenile extranodal NK/T-cell lymphoma. 61
32665697 2020
26
[The diagnostic value of flow cytometry in patients with lymphoma associated hemophagocytic syndrome]. 61
33256339 2020
27
Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. 61
33277620 2020
28
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. 61
32766875 2020
29
CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. 61
32314054 2020
30
Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation - a case report and a review of the literature. 61
32689856 2020
31
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. 61
32844695 2020
32
m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. 61
33205540 2020
33
A nasal swelling revealing a metastatic testicular extranodal NK/T-cell lymphoma: A case report and a review of literature. 61
33102056 2020
34
[Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma]. 61
33333695 2020
35
Application of 3D-print silica bolus for nasal NK/T-cell lymphoma radiation therapy. 61
32960262 2020
36
Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. 61
32627928 2020
37
Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. 61
33261029 2020
38
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. 61
33292562 2020
39
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. 61
32617699 2020
40
Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens. 61
33129745 2020
41
[Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma]. 61
33113633 2020
42
[Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance]. 61
32992412 2020
43
Primary cutaneous nasal-type NK/T-cell lymphoma presenting as purpuric nodules on the lower leg. 61
33005711 2020
44
[Clinical characteristics and survival analysis of primary intestinal extranodal NK/T-cell lymphoma, nasal type]. 61
33190438 2020
45
Transcriptome complexity in intravascular NK/T-cell lymphoma. 61
32188628 2020
46
A potential treatment option for elderly non-Hodgkin lymphoma patients with multiple comorbidities: Two case reports and literature review. 61
33132079 2020
47
Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus. 61
32514927 2020
48
Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. 61
33050643 2020
49
sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells. 61
32945520 2020
50
[Clinicopathological features of primary EB virus positive nodal T/NK cell lymphoma]. 61
32992414 2020

Variations for Mature T-Cell and Nk-Cell Lymphoma

Expression for Mature T-Cell and Nk-Cell Lymphoma

Search GEO for disease gene expression data for Mature T-Cell and Nk-Cell Lymphoma.

Pathways for Mature T-Cell and Nk-Cell Lymphoma

Pathways related to Mature T-Cell and Nk-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.83 NCAM1 ICOSLG CD8A CD4 CD2
2 11.62 NCAM1 CD8A CD5 CD4 CD2
3
Show member pathways
11.55 HDAC6 HDAC11 HDAC1
4 11.48 NCAM1 CD8A CD4
5 11.4 HDAC6 HDAC11 HDAC1
6 11.35 CD8A CD7 CD5 CD4 CD2
7
Show member pathways
11.26 HDAC6 HDAC11 HDAC1
8 10.97 HDAC6 HDAC11 HDAC1
9 10.92 NCAM1 CD8A CD7 CD4 CCR6

GO Terms for Mature T-Cell and Nk-Cell Lymphoma

Cellular components related to Mature T-Cell and Nk-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.17 NCAM1 ICOSLG CD8A CD5 CD4 CD2
2 histone deacetylase complex GO:0000118 9.13 HDAC6 HDAC11 HDAC1

Biological processes related to Mature T-Cell and Nk-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone deacetylation GO:0016575 9.5 HDAC6 HDAC11 HDAC1
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 CD8A CD7 CD4 ALK
3 positive regulation of signaling receptor activity GO:2000273 9.4 HDAC6 HDAC1
4 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.37 MIR199A1 MIR17
5 positive regulation of hydrogen peroxide-mediated programmed cell death GO:1901300 9.26 MIR17 HDAC6
6 histone H3 deacetylation GO:0070932 9.13 HDAC6 HDAC11 HDAC1
7 T cell activation GO:0042110 9.02 ICOSLG CD8A CD7 CD4 CD2

Molecular functions related to Mature T-Cell and Nk-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.35 CD7 CD5 CD4 CD2 CCR6
2 histone deacetylase activity GO:0004407 9.33 HDAC6 HDAC11 HDAC1
3 protein deacetylase activity GO:0033558 9.26 HDAC6 HDAC1
4 NAD-dependent histone deacetylase activity (H3-K14 specific) GO:0032041 8.8 HDAC6 HDAC11 HDAC1

Sources for Mature T-Cell and Nk-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....